RBC Capital maintained an Outperform rating on Kymera Therapeutics (KYMR) on February 26, 2026. This KYMR analyst rating action included a price target increase to $108, according to StreetInsider, and registered a small intraday move of 0.15% ($0.14). The firm listed the call at 11:56 AM ET. Kymera’s market cap stands at $7,602,307,441, and investors should weigh the rating against recent company activity, including an ATM offering and insider sales. Meyka AI rates KYMR with a grade of B+.
KYMR analyst rating: RBC Capital maintained Outperform and raised PT
On February 26, 2026 at 11:56 AM, RBC Capital maintained an Outperform on Kymera Therapeutics and raised the price target to $108, per StreetInsider source. The published note showed a modest stock reaction of 0.15% ($0.14) at the time of the entry. This is the lone reported update in the latest cycle of analyst activity for KYMR.
What an Outperform rating means for investors
An Outperform indicates RBC expects KYMR to beat the broader market or peers over the next 12 months. For investors this typically signals relative conviction versus a Hold or Underperform stance. It does not guarantee short-term gains and should be combined with valuation, pipeline milestones, and risk tolerance when acting.
How the rating ties to short-term stock moves and recent news
The RBC note coincided with minimal intraday price movement, suggesting the market already priced parts of the update. At the same time, Kymera announced a $500 million at-the-market offering and the CEO sold $2.7 million in shares, both of which can counterbalance positive analyst sentiment source. These corporate actions may increase share supply and weigh on price despite the maintained Outperform.
Historical analyst coverage and continuity
Recent filings show only one formal rating update in this list, from RBC on Feb 26, 2026. Historically, Kymera has attracted coverage around clinical readouts and quarterly results, with periodic revisions to price targets tied to trial milestones and guidance. Investors should monitor both the frequency and drivers of updates to understand shifts in consensus.
Risks and catalysts investors should watch
Key catalysts include upcoming clinical readouts, regulatory news, and quarterly financials that can validate RBC’s outlook. Key risks are dilution from the ATM program, insider sales that may signal liquidity needs, and clinical trial setbacks. Watch milestones and cash runway closely to gauge whether the $108 price target remains realistic.
Meyka AI grade and how to use analyst insight
Meyka AI rates KYMR with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Use this grade as a summary input alongside the KYMR analyst rating and firm price targets when forming an investment view. These grades are not guaranteed and we are not financial advisors.
Final Thoughts
RBC Capital’s decision to maintain Outperform on Kymera Therapeutics and lift the price target to $108 on Feb 26, 2026 keeps analyst sentiment tilted positive for KYMR. The KYMR analyst rating reinforces a favorable view versus peers, but nearby corporate moves, including a $500 million ATM and insider selling, create offsetting pressure. With a market cap of $7,602,307,441 and the recent modest market reaction of 0.15% ($0.14) at the time of the update, investors should treat the rating as one data point. Monitor upcoming clinical and financial catalysts, and consider the Meyka AI grade of B+ as a complement to analyst views. Combine the rating with valuation, pipeline milestones, and capital structure analysis before adjusting positions.
FAQs
What exactly did RBC Capital change for Kymera on Feb 26 2026?
RBC Capital maintained an Outperform rating for Kymera and raised the price target to $108 on Feb 26, 2026. The note was logged at 11:56 AM and produced a small market move of 0.15% ($0.14).
How should I use the KYMR analyst rating in my investment decisions?
Use the KYMR analyst rating as one input among valuation, clinical catalysts, and risk. An Outperform signals relative upside expectations, but verify with cash runway, trial readouts, and possible dilution from the ATM offering.
Does the price target change mean immediate upside for the stock?
A price target change indicates analyst views, not a guarantee of immediate gains. Market reaction depends on whether the update alters expectations beyond what the market already priced, and on corporate actions like the ATM program.
What key events could make the KYMR analyst rating change again?
Major clinical readouts, regulatory milestones, quarterly results that alter guidance, balance sheet shifts from capital raises, or material insider transactions can all prompt analysts to revisit the KYMR analyst rating.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
